C4 Therapeutics
Update in progressCCCC (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
C4 Therapeutics is a clinical-stage biopharmaceutical company developing protein degraders to treat disease. Its lead candidate, Cemsidomide, is an orally bioavailable IKZF1/3 degrader for multiple myeloma, having completed Phase 1. It is advancing CFT8919, an EGFR L858R–selective degrader for NSCLC, and additional degraders for inflammation and neurodegeneration. Partnerships include Roche, Betta Pharmaceuticals, Merck KGaA, and Roche for Degrader–Antibody Conjugates. Founded 2015, in Watertown, MA.
Company score
- Sentiment
- 0.43
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!